Nuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma
Sakari Kosola, Teemu D. Laajala, Iida Payne, Antti Kukkula, Lassi Luomala, Tuomas Mirtti, Kalle Mattila, Paula Vainio, Maria Sundvall, Panu M. Jaakkola · 2026
Read Nuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma by Sakari Kosola, Teemu D. Laajala, Iida Payne, Antti Kukkula, Lassi Luomala, Tuomas Mirtti, Kalle Mattila, Paula Vainio, Maria Sundvall, Panu M. Jaakkola (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13426025.txt.
Description
Kosola and colleagues published a 2026 study on a protein that may forecast kidney cancer outcomes. Clear cell renal cancer often returns after surgery, even when caught early. The team measured a protein called PML inside tumor cell nuclei. Two hospital groups in Finland gave them 364 surgical cases to test.
Patients with high PML levels saw their cancer return far less often. They also lived longer in both hospital groups over long follow-up. In the second group, high PML held its value after adjusting for known risk traits. Follow-up stretched to a median of eight and nine years in the groups. A simple tissue stain could one day sharpen risk talks after surgery. Risk talks after surgery could soon include a PML result as well.
Catalog record
| CREATOR | Sakari Kosola, Teemu D. Laajala, Iida Payne, Antti Kukkula, Lassi Luomala, Tuomas Mirtti, Kalle Mattila, Paula Vainio, Maria Sundvall, Panu M. Jaakkola |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |